Morpholine‐Based Chalcones as Potent and Selective MAO‐B Inhibitors With Preliminary CNS Drug‐Like Properties
ChemMedChem · 12.11.2026 · 21 (21)
DOI: 10.1002/cmdc.70515 ↗Kurz gefasst
Fachartikel in der Zeitschrift ChemMedChem, online erschienen am 30.10.2026. Verfasst von Asmar Taghiyeva und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemistry, Faculty of Science, Istanbul University, Istanbul, Türkiye. Hauptthemen laut MEDLINE: Monoamine Oxidase Inhibitors, Chalcones, Monoamine Oxidase, Morpholines. Die Arbeit nennt 58 Literaturangaben. Gefördert von: the Scientific Research Projects Coordination Unit of Istanbul University.
Abstract (Originalsprache)
A series of morpholine‐based chalcone derivatives containing alkoxy substituents was designed and synthesized using a rapid and environmentally friendly microwave‐assisted protocol. The synthesized compounds were fully characterised by NMR, FTIR, and HRMS analyses and evaluated in vitro against primarily monoamine oxidases, as well as acetylcholinesterase, butyrylcholinesterase, and β‐site amyloid precursor protein cleaving enzyme 1, which are closely associated with neurodegenerative disorders. Although most compounds showed weak inhibition of AChE, BChE, and BACE1, they exhibited potent and selective MAO‐B inhibitory activity. Among them, MBC21 emerged as the most potent MAO‐B inhibitor (IC 50 = 0.069 ± 0.0075 μM; SI 243.33), acting as a competitive and reversible inhibitor. In addition, MBC1, MBC2, and MBC24 displayed notable BChE inhibitory activity, while MBC24 demonstrated multi‐target activity against MAO‐B, AChE, and BChE. Molecular docking and molecular dynamics simulations revealed that the selectivity of MBC21 towards hMAO‐B is associated with stable hydrophobic interactions and π–π stacking with TYR326. Furthermore, in silico ADME prediction, microsomal stability, and PAMPA‐BBB studies demonstrated favorable drug‐like properties, improved metabolic stability, and moderate brain permeability for MBC21 . Taken together, these findings identify MBCs, particularly MBC21 , as promising lead candidates for the development of selective MAO‐B inhibitors for neurodegenerative disease therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Chemistry, Faculty of Science, Istanbul University, Istanbul, Türkiye.
- Institute of Graduate Studies in Science, Istanbul University, Istanbul, Türkiye.
- Department of Pharmacy, College of Pharmacy, Sunchon National University, Suncheon, Republic of Korea.
- Department of Pharmaceutical Sciences and Technology, Birla Institute of Technology, Ranchi, Jharkhand, India.
- DMPK Department, Eurofins Advinus Biopharma Services Private Limited, Bangalore, India.
- Adgyl Lifesciences Private Limited, Bengaluru, India.
ORCID-Profile: Asmar Taghiyeva, Abanish Biswas, Subodh Mondal, Ritika Uppal Mukherjee, Nilüfer Bayrak, Venkatesan Jayaprakash, Man-Jeong Paik, Hoon Kim, Amaç Fatih TuYuN
Förderung
- the Scientific Research Projects Coordination Unit of Istanbul University
Zitieren
APA
Taghiyeva, A., Lim, J., Biswas, A., Mondal, S., Mukherjee, R. U., Basavanakatti, V. N., Bayrak, N., Jayaprakash, V., Paik, M. J., Kim, H., & TuYuN, A. F. (2026). Morpholine‐Based Chalcones as Potent and Selective MAO‐B Inhibitors With Preliminary CNS Drug‐Like Properties. ChemMedChem, 21(21). https://doi.org/10.1002/cmdc.70515
Vancouver
Taghiyeva A, Lim J, Biswas A, Mondal S, Mukherjee RU, Basavanakatti VN, et al. Morpholine‐Based Chalcones as Potent and Selective MAO‐B Inhibitors With Preliminary CNS Drug‐Like Properties. ChemMedChem. 2026;21(21). doi:10.1002/cmdc.70515
BibTeX
@article{Taghiyeva2026,
author = {Taghiyeva, Asmar and Lim, Jaeyeop and Biswas, Abanish and Mondal, Subodh and Mukherjee, Ritika Uppal and Basavanakatti, Vinay N and Bayrak, Nilüfer and Jayaprakash, Venkatesan and Paik, Man-Jeong and Kim, Hoon and TuYuN, Amaç Fatih},
title = {Morpholine‐Based Chalcones as Potent and Selective MAO‐B Inhibitors With Preliminary CNS Drug‐Like Properties},
journal = {ChemMedChem},
year = {2026},
volume = {21},
number = {21},
doi = {10.1002/cmdc.70515}
}
EUVIMED